High-dose melphalan and the development of hematopoietic stem-cell transplantation: 25 years later

J Clin Oncol. 2008 May 10;26(14):2240-3. doi: 10.1200/JCO.2007.14.7827.

Authors

Hillard M Lazarus¹, Gordon L Phillips, Roger H Herzig, David D Hurd, Steven N Wolff, Geoffrey P Herzig

Affiliation

¹ Department of Medicine, University Hospitals Case Medical Center, Ireland Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA.

PMID: 18467711
DOI: 10.1200/JCO.2007.14.7827

No abstract available

MeSH terms

Antineoplastic Agents, Alkylating / administration & dosage
Antineoplastic Agents, Alkylating / adverse effects
Combined Modality Therapy
Hematopoietic Stem Cell Transplantation / adverse effects
Hematopoietic Stem Cell Transplantation / methods*
Hodgkin Disease / therapy
Humans
Leukemia, Myeloid / therapy
Lymphoma, Non-Hodgkin / therapy
Melphalan / administration & dosage*
Melphalan / adverse effects
Multiple Myeloma / therapy
Myeloablative Agonists / administration & dosage
Myeloablative Agonists / adverse effects
Neoplasms / therapy*
Neoplasms, Germ Cell and Embryonal / therapy
Neuroblastoma / therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

Substances

Antineoplastic Agents, Alkylating
Myeloablative Agonists
Melphalan